X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs CIPLA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD CIPLA LUPIN LTD/
CIPLA
 
P/E (TTM) x 17.9 45.5 39.3% View Chart
P/BV x 3.4 3.7 90.4% View Chart
Dividend Yield % 0.7 0.3 216.0%  

Financials

 LUPIN LTD   CIPLA
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
CIPLA
Mar-17
LUPIN LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,750622 281.4%   
Low Rs1,384458 301.9%   
Sales per share (Unadj.) Rs387.4181.9 213.0%  
Earnings per share (Unadj.) Rs56.612.9 440.0%  
Cash flow per share (Unadj.) Rs76.829.3 262.1%  
Dividends per share (Unadj.) Rs7.502.00 375.0%  
Dividend yield (eoy) %0.50.4 129.3%  
Book value per share (Unadj.) Rs298.9155.7 192.0%  
Shares outstanding (eoy) m451.58804.51 56.1%   
Bonus/Rights/Conversions ESOPSESOP-  
Price / Sales ratio x4.03.0 136.2%   
Avg P/E ratio x27.742.0 65.9%  
P/CF ratio (eoy) x20.418.4 110.7%  
Price / Book Value ratio x5.23.5 151.1%  
Dividend payout %13.215.5 85.2%   
Avg Mkt Cap Rs m707,513434,516 162.8%   
No. of employees `00016.823.0 72.9%   
Total wages/salary Rs m28,49526,338 108.2%   
Avg. sales/employee Rs Th10,418.36,349.1 164.1%   
Avg. wages/employee Rs Th1,697.01,143.0 148.5%   
Avg. net profit/employee Rs Th1,523.0449.3 338.9%   
INCOME DATA
Net Sales Rs m174,943146,302 119.6%  
Other income Rs m1,0652,287 46.6%   
Total revenues Rs m176,008148,589 118.5%   
Gross profit Rs m44,93124,758 181.5%  
Depreciation Rs m9,12213,229 69.0%   
Interest Rs m1,5251,594 95.7%   
Profit before tax Rs m35,34912,222 289.2%   
Minority Interest Rs m-720-   
Prior Period Items Rs m83-70 -118.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m9,7851,798 544.3%   
Profit after tax Rs m25,57510,354 247.0%  
Gross profit margin %25.716.9 151.8%  
Effective tax rate %27.714.7 188.2%   
Net profit margin %14.67.1 206.6%  
BALANCE SHEET DATA
Current assets Rs m119,54287,370 136.8%   
Current liabilities Rs m61,20633,081 185.0%   
Net working cap to sales %33.337.1 89.9%  
Current ratio x2.02.6 73.9%  
Inventory Days Days7687 87.4%  
Debtors Days Days9062 144.2%  
Net fixed assets Rs m131,660111,567 118.0%   
Share capital Rs m9031,609 56.1%   
"Free" reserves Rs m134,073123,645 108.4%   
Net worth Rs m134,976125,254 107.8%   
Long term debt Rs m56,47836,454 154.9%   
Total assets Rs m266,073209,532 127.0%  
Interest coverage x24.28.7 278.9%   
Debt to equity ratio x0.40.3 143.8%  
Sales to assets ratio x0.70.7 94.2%   
Return on assets %10.25.7 178.6%  
Return on equity %18.98.3 229.2%  
Return on capital %19.38.5 226.6%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m81,88551,066 160.3%   
Fx outflow Rs m21,50617,678 121.7%   
Net fx Rs m60,37833,388 180.8%   
CASH FLOW
From Operations Rs m41,14823,824 172.7%  
From Investments Rs m-25,287-13,127 192.6%  
From Financial Activity Rs m4,332-13,239 -32.7%  
Net Cashflow Rs m20,193-2,478 -814.9%  

Share Holding

Indian Promoters % 46.6 16.0 291.3%  
Foreign collaborators % 0.2 20.8 1.0%  
Indian inst/Mut Fund % 11.3 12.2 92.6%  
FIIs % 31.9 23.7 134.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.1 26.2 38.5%  
Shareholders   98,259 161,166 61.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  WYETH LTD  ASTRAZENECA PHARMA  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Sep 22, 2017 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS